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Abstract: Cytokines produced by both immune and non-immune cells are 
likely to play roles in the development and/or progression of psychiatric 
disorders. Indeed, many investigators have compared the blood cytokine 
levels in psychiatric patients with those of healthy controls or 
monitored their levels in patients during disease progression to identify 
biomarkers. Nevertheless, very few studies have confirmed that such 
cytokines remain stable in healthy individuals through periods of weeks 
and months. This is an important issue to consider before using blood 
cytokine levels as biomarkers of disease traits, disease state, or 
treatment response. Although multiplex assay technology represents an 
advance in identifying biomarkers because it allows simultaneous 
examination of large panels of analytes from a small volume of sample, it 
is necessary to verify whether these assays yield enough sensitivity and 
reproducibility when applied to the blood from neuropsychiatric patients. 
Therefore, we compared two multiplex immunoassays, the bead-based 
Luminex® (Bio-Rad) and the electro-chemiluminescence-based V-plex® 
(MesoScaleDiscovery), for the detection and quantification of 31 
cytokines, chemokines and growth factors in both the sera and plasma of 
patients with major depressive episodes (MDE) and age- and sex-matched 
healthy control subjects during a 30-week period. Although both platforms 
exhibited low coefficients of variability (CV) between the duplicates in 
the calibration curves, the linearity was better in general for the V-
PLEX® platform. However, neither platform was able to detect the absolute 
values for all of the tested analytes. Among the 16 analytes that were 
detected by both assays, the intra-assay reproducibility was in general 
better with the V-PLEX® platform. Although it is not a general rule that 
the results from sera and plasma will be correlated, consistent results 
were more frequent with the V-PLEX® platform. Furthermore, the V-PLEX® 
results were more consistent with the gold standard ELISA simplex assay 
for IL-6 in both sera and plasma. The intra-individual variability of the 
measurements, among the sera and plasma for the 4 samples harvested from 
each healthy individual, was low for Eotaxin, G-CSF, IL-4, IL-7, IL-9, 
IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β and VEGF, but 
intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, 
these data suggest that extreme caution is needed in translating the 
results of multiplex cytokine profiling into biomarker discovery in 
psychiatry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dear Editor,  
 
 We thank you and the Editor in chief, Robert Dantzer, for reaching the conclusion to 
ultimately publish our manuscript. Following your suggestion, we changed the tiltle to: "How 
to: Measuring blood cytokines in biological psychiatry using commercially available 
multiplex immunoassays". 
 We were concerned by the persistent negative comments of Reviewer#3, stressing out 
that our comparison between the two platforms we have worked with suffers a number of 
theoretical and technical limitations because of the difference in the number of analytes that 
are measured by each platform and the lack of assessment of the between assay variability. 
Therefore, and following your recommandations, we made as clear as possible in the 
discussion section the limits of our study, and we also introduced some new conclusions 
supported by new results we just obtained this month: 
“Our findings have several important technical and theoretical limitations. First, we 
could not compare exactly the same sets of cytokines on both platforms on the basis of 
the commercial availability, and it has previously been observed that assay 
performance decreases with increasing numbers of markers on a panel (Chaturvedi et 
al., 2011). It will be important in the future to follow up with studies to compare larger 
sets of cytokines as similar to each other as possible, because recent investigations in 
the field of biomarker discovery have revealed new candidates for promising proteins. 
Secondly, we did not address the inter-assay variability on each platform, which is an 
important factor to consider especially when investigating large samples that cannot 
be processed with a single batch of reagents or for longitudinal studies when assaying 
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 2 
the samples at different days over long periods of time. Third, our results should be 
considered to be preliminary on the basis of the relatively small sample size that 
makes any group comparison between healthy control and patients inappropriate. Of 
note, for the purpose of another study, all serum samples assayed in the present study, 
and obtained from healthy control and MDE patients at their first visit, have been 
tested again on the MSD platform with a different batch of reagents and a two-year 
interval (data not shown). The same panels of cytokines were assayed as well as an 
additional chemokine panel. A comparative analysis of old and new measurements of 
cytokine concentrations revealed robust correlations for IFN-γ, IL-6, IL-8, IL-10, IL-
12p40, IL-15, IL-16, TNF, TNF-β, and VEGF (data not shown), suggesting a strong 
inter-assay stability for these analytes on the MSD platform. Moreover, the new 
measurements for IP-10 and MIP-1β obtained on the MSD platform strongly 
correlated with previous measurements obtained with the Luminex platform (data not 
shown), suggesting that these assays exhibit low intra- and inter-assay variability on 
both platforms. “ 
 
 With the hope of a final approval of our manuscript in Psychoneuroendocrinology. 
Sincerely, 
 
El Chérif IBRAHIM 
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Abstract 
Cytokines produced by both immune and non-immune cells are likely to play roles in the 
development and/or progression of psychiatric disorders. Indeed, many investigators have 
compared the blood cytokine levels in psychiatric patients with those of healthy controls or 
monitored their levels in patients during disease progression to identify biomarkers. 
Nevertheless, very few studies have confirmed that such cytokines remain stable in healthy 
individuals through periods of weeks and months. This is an important issue to consider 
before using blood cytokine levels as biomarkers of disease traits, disease state, or 
treatment response. Although multiplex assay technology represents an advance in 
identifying biomarkers because it allows simultaneous examination of large panels of 
analytes from a small volume of sample, it is necessary to verify whether these assays yield 
enough sensitivity and reproducibility when applied to the blood from neuropsychiatric 
patients. Therefore, we compared two multiplex immunoassays, the bead-based Luminex® 
(Bio-Rad) and the electro-chemiluminescence-based V-plex® (MesoScaleDiscovery), for the 
detection and quantification of 31 cytokines, chemokines and growth factors in both the sera 
and plasma of patients with major depressive episodes (MDE) and age- and sex-matched 
healthy control subjects during a 30-week period. Although both platforms exhibited low 
coefficients of variability (CV) between the duplicates in the calibration curves, the linearity 
was better in general for the V-PLEX® platform. However, neither platform was able to detect 
the absolute values for all of the tested analytes. Among the 16 analytes that were detected 
by both assays, the intra-assay reproducibility was in general better with the V-PLEX® 
platform. Although it is not a general rule that the results from sera and plasma will be 
correlated, consistent results were more frequent with the V-PLEX® platform. Furthermore, 
the V-PLEX® results were more consistent with the gold standard ELISA simplex assay for 
IL-6 in both sera and plasma. The intra-individual variability of the measurements, among the 
sera and plasma for the 4 samples harvested from each healthy individual, was low for 
Eotaxin, G-CSF, IL-4, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β 
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and VEGF, but intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, these 
data suggest that extreme caution is needed in translating the results of multiplex cytokine 
profiling into biomarker discovery in psychiatry.  
 
Keywords: Cytokine, Psychiatry, Inflammation, Multiplex immunoassay 
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1. Introduction 
Cytokines belong to a large family of polypeptides that are produced by various cell types in 
the body, including the cells of the immune system. In particular, pro-inflammatory cytokines 
such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF) are rapidly secreted in 
response to a pathogen infection, whereas anti-inflammatory cytokines, such as IL-4, IL-10 
and IL-13 have the opposite effects. Binding of the cytokines to specific receptors on the cell 
surfaces triggers events inside the cell that lead to altered gene expression profiles and cell 
function (Bezbradica and Medzhitov, 2009). In the last two decades, studies have shown that 
cytokines produced in peripheral tissues can access the central nervous system and interact 
with the cytokine network in the brain to influence virtually every aspect of brain function 
relevant to behavior, including neurotransmitter metabolism, neuroendocrine function, 
synaptic plasticity, and the neurocircuits that regulate mood, feeding, sleep, motor activity, 
motivation, anxiety and alarm (Capuron et al., 2001; Dantzer et al., 2011; Marshall and Born, 
2002; Raison et al., 2006). 
During the host immune response to pathogen invasion, the release of pro-
inflammatory cytokines is usually transient and regulated by anti-inflammatory mechanisms. 
Consequently, the behavioral effects triggered by the increased serum cytokine levels have 
developped as an adaptive, temporary and controlled reaction of the brain to immune signals 
(Medzhitov, 2008). Nevertheless, when an immune challenge becomes chronic or 
unregulated, as occurs in patients who are receiving chronic cytokine treatments or those 
exposed to chronic medical illness or psychological stress, the cytokines may contribute to 
the development of clinically relevant behavioral symptoms and neuropsychiatric diseases, 
including major depression (Raison and Miller, 2013). In support of this hypothesis, 
depressive symptoms have been shown to be associated with increased serum and plasma 
concentrations of TNF, IL-6 and C-reactive protein (Dowlati et al., 2010; Goldsmith et al., 
2016; Strawbridge et al., 2015; Valkanova et al., 2013). Most importantly, recent longitudinal 
studies have extended these cross-sectional observations by reporting that increased 
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inflammatory markers in non-depressed individuals predict the later development of major 
depression (Gimeno et al., 2009; Pasco et al., 2010; van den Biggelaar et al., 2007).  
Based on these observations, several authors have suggested that specific cytokines 
could be used as biomarkers in psychiatric diseases (Stuart and Baune, 2014), and even that 
cytokine-blocking reagents could be used to treat or prevent psychiatric symptoms (Fond et 
al., 2014; Kohler et al., 2014; Miller and Raison, 2015). 
Recently, biomarkers for neuropsychiatric diseases have been classified into those of 
risk, diagnosis/trait, state, stage, treatment response and prognosis (Davis et al., 2015). In 
mood disorders, several studies have suggested that the chronic mild inflammation indicated 
by elevated C-reactive protein (Courtet et al., 2015; Rapaport et al., 2015; Uher et al., 2014) 
as well as the quantification of the levels of inflammatory cytokines such as IL-6, IL-10 and 
TNF (de Witte et al., 2014; Ducasse et al., 2015b; Haapakoski et al., 2015; Halaris et al., 
2015; Rethorst et al., 2013) could prove to be useful biomarkers for improved diagnosis and 
the detection of treatment refractoriness (Strawbridge et al., 2015), as well as indicators of 
the risk of suicide. As an increasing number of inflammatory factors are tested, an emerging 
picture supports the idea that a complex network of cytokines is involved in the 
pathophysiology of disease such as major depression (Dahl et al., 2014). 
It is known that many blood mediators present substantial individual variations among 
healthy subjects (Katsuura et al., 2011), and that acute psychological stress as well as acute 
exercise also produce robust effects on some circulating inflammatory factors in healthy 
people (Hallberg et al., 2010; Katsuura et al., 2010; Reihmane et al., 2012; Steptoe et al., 
2007). In addition, most of the studies in this field have not considered the possibility that 
inflammatory factors measured in peripheral blood might exhibit a high degree of variability 
independent of any neuropsychiatric disorder. Some investigators have recognized the risk 
of making single measurements in healthy controls when assessing the variation due to 
antidepressant treatment in patients, but they emphasized that the previously obtained 
measurements were fairly stable, although this has not been documented in the literature 
(Halaris et al., 2015). Therefore, as a prerequisite for establishing biomarkers, investigators 
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should define which factors actually exhibit stable levels in the circulating biofluids over days, 
weeks, and seasons in healthy adult subjects. Once this is established, it will be possible to 
distinguish real-time state-related protein concentration changes that are normalized by 
remission or by antidepressant treatment from the genetically and epigenetically driven 
physiological or stochastic variations that occur in healthy individuals. Moreover, even the 
previous results remained only partially reproducible. Although there are several possible 
explanations for these discrepancies (Zhou et al., 2010), reliability of the tools is one of the 
first steps required in biomarker development to avoid jumping to premature negative or 
positive conclusions (Niculescu et al., 2015). 
Although the enzyme-linked immunosorbent assay (ELISA) technique has been 
widely used to measure serum cytokine levels in clinical studies, the recent development of 
multiplex immunoassays now offers the possibility of simultaneously measuring the levels of 
expression of large panels of proteins using a small volume of sample and at an affordable 
price (Altara et al., 2015; Butler et al., 2015; Guest et al., 2011; Halaris et al., 2015; Ho et al., 
2015; Janelidze et al., 2013; Nielsen et al., 2015; Schwarz et al., 2012). Nevertheless, it is 
important for the new and constantly upgraded multiplex technologies to prove that their 
performance is at least equal to the ‘gold standard’ ELISA for each analyte tested in the 
combinations (Bastarache et al., 2014). In addition, the use of complex biological matrices 
such as sera or plasma must be used to mimic as closely as possible the biological test as it 
is planned to be used in clinical diagnostics. In biological human fluids, the seasonal, 
hormonal, and circadian physiological variability in the circulating concentrations of 
cytokines/chemokines/growth factors remains poorly investigated both in psychiatric patients 
as a function of their treatments as well as in healthy subjects. Furthermore, large differences 
exist among individuals (Agorastos et al., 2014; Biancotto et al., 2013; Mueller et al., 2012).  
Among the various multiplex platforms, the fluorescent bead-based immunoassay 
Luminex® (Bio-Rad) and the electro-chemiluminescence immunoassay V-plex® (Meso Scale 
Discovery) technologies dominate the market (Rosenberg-Hasson et al., 2014). Thus far, 
very few investigators have compared these technologies and evaluated the limits of 
R. Belzeaux et al. 
 7 
quantification and intra-assay reproducibility for assay of human blood (Breen et al., 2011; 
Chowdhury et al., 2009; Fu et al., 2010; Nechansky et al., 2008; Toedter et al., 2008). 
Therefore, in the context of blood biomarker discovery in psychiatric disorders, we have 
aimed to evaluate whether the levels of circulating cytokines/chemokines/growth factors that 
have been identified as candidate biomarkers vary during periods of weeks and months in 
healthy individuals. For that purpose, we have tested the reliability of the two leading 
multiplex technologies, i.e. Bio-Plex 200 (Bio-Rad) with Luminex® Cytokine 27-plex assay 
and QuickPlex (V-PLEX®®) with V-PLEX® Proinflammatory and Cytokine panels (20 
markers) using longitudinally collected sera and plasma from both healthy subjects and 
patients suffering from a major depressive episode (MDE). 
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2. Materials and methods 
 
2.1 Populations 
Blood sera and plasma samples were obtained during a 30-week prospective evaluation of a 
cohort of 10 patients with a MDE according to DSM-IV during a severe depressive episode 
(Hamilton Depression Rating Scale – 17 items (HDRS-17) = 23.3 at inclusion), and 10 sex-
and age-matched healthy controls. Four visits during the follow-up period (inclusion, 2, 8 and 
30 weeks later) allowed for clinical assessment and biological sampling. An extensive clinical 
and psychological examination, using both Structured Clinical Interview for DSM Disorders 
(First et al., 2002) and a self-rating questionnaire, as well as clinical and biological 
examinations (including body temperature, blood cell count) were used to determine the 
absence of any medical conditions or any psychiatric disorders in the healthy controls. We 
used the same procedure to exclude any patients with medical comorbidities. None of the 
subjects had received any vaccinations within a month before the inclusion. Moreover, to 
confirm the intra-individual stability measured in healthy subjects, 10 additional healthy 
controls were included. All subjects gave informed written consent. The study was conducted 
in accordance with the latest version of the Declaration of Helsinki and was approved by the 
appropriate French ethical and medical authorities. It was part of an ongoing larger study 
registered in ClinicalTrials.gov with ID: NCT02209142.  
 
2.2 Blood samples 
Peripheral blood samples were obtained from fasting subjects between 7:00 am and 9:00 am 
on workdays. Five milliliters of peripheral blood was drawn by venipuncture into both serum 
and K2EDTA Vacutainer tubes. For the serum collection, the blood was allowed to clot for 1 
hour before centrifugation (1500 x g, 10 min). The serum and plasma samples were stored in 
0.5 ml aliquots at -80°C. For the measurements of the blood cytokine levels, the serum and 
plasma samples were thawed on ice, and 50-μl aliquots were prepared and stored at -80°C. 
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2.3 Bio-Plex immunoassay 
The serum and plasma levels of basic fibroblast growth factor (bFGF), eotaxin (CCL-11), 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, 
IL-12p70, IL-13, IL-15, IL-17, IFN-inducible protein-10 (IP-10; CXCL10), monocyte 
chemotactic protein 1 (MCP-1; CCL-2), macrophage inflammatory protein 1 α  (MIP-1α; CCL-
3), MIP-1β (CCL-4), platelet-derived growth factor BB (PDGF-BB), RANTES (CCL-5), TNF, 
and vascular endothelial growth factor (VEGF) were analyzed using the Bio-Plex Pro Human 
Cytokine 27-plex Assay (Bio-Rad) according to the manufacturer’s instructions. The serum 
and plasma samples were diluted 4-fold and run in duplicate. The samples from the 4 time 
points of each 10 healthy control subjects and 10 MDE patients were run in a total of 4 plates 
to measure the serum and plasma cytokine concentrations. Two lots of the reagents were 
used for the entire study (plate and standards): one for the sera and one for the plasma 
samples. A minimum of 50 beads per cytokine was acquired. The median fluorescence 
intensities were collected on a Bio-Plex 200 instrument (Bio-Rad) using Bio-Plex Manager 
software version 6.0 (Bio-Rad). Standard curves for each cytokine were generated using the 
premixed lyophilized standards provided in the kits. Serial 4-fold dilutions of the standards 
were run to generate a 9-standard concentration set, and the diluent alone was used as a 
blank. The cytokine concentrations in the samples were determined from the standard curve 
using a 5-parameter logistic fit curve to transform the mean fluorescence intensities into 
concentrations. The lower limit of quantification (LLOQ) was determined for each cytokine 
and for each plate as the lowest standard for which both duplicate measurements were 
above background values (Table 1). The upper limit of quantification (ULOQ) was 
determined for each cytokine and for each plate as the highest standard that did not reach 
saturation (Table 1). 
 
2.4 V-plex® immunoassays 
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The serum and plasma levels of IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8 (CXCL8), IL-10, IL-12p70, 
IL-13, and TNF were measured using the V-plex Proinflammatory Panel 1 (MSD). The serum 
levels of GM-CSF, IL-1α, IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, and VEGF 
were measured using the V-plex Cytokine Panel 1 (MSD). All assays were performed 
according to the manufacturer’s instructions. The serum and plasma samples were diluted 
2.6-fold. The samples from the 4 time points from each of the 20 healthy controls and 10 
MDE patients were run in duplicate. Those from the additional 10 healthy controls were run 
as single samples. A total of 12 plates were used to measure the serum and plasma cytokine 
concentrations. Two lots of the reagents were used for the entire study (plate and standards): 
one for the sera and one for the plasma samples. The data were acquired on the V-plex® 
Sector Imager 2400 plate reader and analyzed using the Discovery Workbench 3.0 software 
(MSD). The standard curves for each cytokine were generated using the premixed 
lyophilized standards provided in the kits. Serial 4-fold dilutions of the standards were run to 
generate a 7-standard concentration set, and the diluent alone was used as a blank. The 
cytokine concentrations were determined from the standard curve using a 4-parameter 
logistic fit curve to transform the mean light intensities into concentrations. The lower limit of 
quantification (LLOQ) was determined for each cytokine and for each plate as the lowest 
standard for which both duplicate measurements were above the duplicate background 
values (Table 1). The upper limit of quantification (ULOQ) was determined for each cytokine 
and for each plate as the highest standard that did not reach saturation (Table 1). 
 
2.5 ELISA 
The serum levels of IL-6 were measured using a Quantikine High Sensitivity ELISA kit (R&D) 
according to the manufacturer’s instructions. Serial 2-fold dilutions of the standard were used 
to generate a 7-standard concentration set. The diluent was used as a blank. The serum and 
plasma samples were diluted 2-fold and run separately on a single plate. The data were 
acquired using an Infinite F200 plate reader (Tecan) and Magellan version 6.5 software 
R. Belzeaux et al. 
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(Tecan). The IL-6 concentrations were determined from the standard curve using a 4-
parameter logistic fit curve to transform the mean optical densities into concentrations.  
 
2.6 Statistical analysis 
A detailed workflow for the analyses is provided in Supplementary Figure 1. The dynamic 
range of the measurements for each plate corresponded to the values for the concentrations 
between the LLOQ and the HLOQ. A cytokine was considered detectable with either platform 
only if at least 60% of the duplicate measures of the cytokine concentrations lay within the 
LLOQ-HLOQ window (i.e., the detection range) for the sera from either the patient or control 
group. The reproducibility of the calibrator dilutions and reproducibility of intra-assay 
replicates were evaluated by calculating the coefficient of variation (CV) in % (i.e., CV = 
standard deviation/mean*100). Since there is no consensus on the appropriate threshold for 
objective judgment of the reliability of a biological test, we have set up a threshold of CV < 
15% as revealing good reliability and a CV < 5% for very good reliability. The measurements 
of identical cytokines performed on both platforms were compared using Spearman’s 
coefficient of correlation. The intra-individual serum cytokine variability in the healthy subjects 
was evaluated using the intra-class correlation coefficient (ICC), which reflects the relative 
balance of between- and within-person variance components (Agalliu et al., 2013; Clendenen 
et al., 2010; Dossus et al., 2009; Epstein et al., 2013; Gu et al., 2009; Hardikar et al., 2014; 
Hofmann et al., 2011; Navarro et al., 2012; Wong et al., 2008). As suggested by Rosner 
(Rosner, 2000), an ICC ≥ 0.75 indicates excellent reproducibility, 0.4 ≤ ρ <0.75 indicates fair 
to good reproducibility, and <0.4 indicates poor reproducibility. Moreover, an ICC of at least 
0.55 has been established as a threshold for cytokines worthy of consideration (Giraudeau, 
1996; Gu et al., 2009). All statistical tests were conducted using the IBM SPSS Statistics v22 
software. A p-value < 0.05 was considered as significant. 
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3. Results 
3.1. Standard curves 
We studied a total of 31 cytokines. Of these, 16 were detected on both platforms, 11 were 
detected on the Luminex® platform only, and 4 were detected on the V-plex® platform only. 
The intra-assay variability was good (CV < 15%) for all cytokines on both platforms, and 
excellent (CV < 5%) for 15 (out of 20) cytokines on the V-plex® platform and 24 (out of 27) 
on the Luminex® platform (Table 1). When the 16 cytokines that were detected on both 
platforms were considered, the LLOQ was lower on the V-plex® platform than on the 
Luminex® platform, except for IL-1ß and IL-13 (Table 1). In contrast, the detection range, 
measured as the ratio between the HLOQ and the LLOQ, was higher on the Luminex® 
platform than on the V-PLEX® platform for all cytokines except for IL-2 and IL-15 (Table 1). 
Nevertheless, when considering the five consecutive four-fold calibrator dilutions that formed 
the best regression line, the linearity was much closer to 100% for all tested analytes except 
for IFN-γ and IL-13 on V-PLEX® compared to Luminex® platform as shown in 
Supplementary Figure 1 and Table 1.   
 
3.3. Serum and plasma cytokine levels 
Among the 31 proteins that we studied, several were below the LLOQ for more than 60% of 
both the tested serum and plasma samples (Tables 2 and 3). This was the case for IL-15 and 
MCP-1 on the Luminex® platform, IL-4, IL-12p70 and IL-13, and GM-CSF on the V-plex® 
platform, and IL-2 on both platforms. In general, the comparison of the percentages that were 
detected in the plasma versus the sera showed that a smaller proportion of the plasma 
values for most of the analytes were below the LLOQ especially with the Luminex® platform. 
For example, although IL-15, GM-CSF and IFN-γ were undetectable in all sera, they were 
detected in half, almost all and all of the plasma samples, respectively. Of the 16 cytokines 
measured by both platforms, only IL-7, IL-8, TNF and VEGF were detected in all or almost 
sera and plasma samples.  
R. Belzeaux et al. 
 13 
For the analytes that were detected in more than 60% of the samples on at least one 
platform, we measured the intra-assay reproducibility by calculating the CV for the 
duplicates. Parallel to the increased detectability in plasma for the Luminex® platform, the 
intra-assay reproducibility was also better in plasma compared to sera with CV < 15% 
observed in 22 assays compared 13 (out of 27), respectively. The results from the V-plex® 
platform were more similar between the sera and plasma, with approximately half of the 
cytokines demonstrating a CV < 15%. Despite the overall heterogeneity of the performance 
for both platforms, in examining the assays for which very good reproducibility was obtained, 
a slight advantage might be given to the V-plex® platform on the basis that more analytes 
demonstrated CVs that were < 5% (30% for MSD versus 11% for Luminex for sera and 20% 
versus 7% for plasma). 
There is no absolute biological reason that would mandate similar and/or correlated 
concentration of all analytes in sera and plasma samples from the same individual (Altara et 
al., 2015; Chaturvedi et al., 2011; Clendenen et al., 2010; Dossus et al., 2009; Rosenberg-
Hasson et al., 2014; Wong et al., 2008). We therefore determined on each platform the 
degree of correlation between serum and plasma measurements. As shown in Table 4 
(samples of the first visit only: the results for all four visits are reported on Supplementary 
Tables 1 and 2), among the analytes that were detected in over 60% of both sera and 
plasma with adequate reproducibility of the duplicates, only 5 of 16 (Eotaxin, IP-10, MIP-1β, 
IL-10 and IL-13) were correlated for the two blood fluids in the Luminex® analyses, whereas 
7 of 10 (IL-12p40, IL-16, IL-10, IFN-γ, IL-6, IL-15, TNF, and VEGF) demonstrated strongly 
similar of measurements on the MSD platform. Specifically, the correlation of measurements 
obtained for IL-6 on both multi-assay platforms is shown in Supplementary Fig. 2A and B. 
Among the 16 cytokines detected by both immunoassays, only IL-8, IL-10, TNF and 
VEGF exhibited low intra-assay variability on both platforms for the sera (Table 2 and 
Supplementary Figure 2A and C), whereas IFN-γ, IL-6, IL-7, IL-8, IL-10, TNF, and VEGF 
fulfilled these requirements for the plasma (Table 3). For these proteins, we used the 
Spearman non-parametric correlation test to measure the correlation between the two 
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platforms. Table 5 reports the results for the samples from the first visit only, and the results 
for all four visits are shown in Supplementary Tables 3 and 4 for the serum and plasma 
samples, respectively. Correlations between the platforms were observed only for IL-8 in 
serum and for IL-6 in plasma. Moreover, the correlation for IL-6 was not maintained in all 
visits (Supplementary Table 3). Finally, the correlation was very high in both fluids at all visits 
only for VEGF. 
Furthermore, with the exception of IL-8, the absolute cytokine concentrations 
measured by the two platforms were substantially different and exceeded 10-fold for IL-6, IL-
10, IL-17 and TNF and 200-fold for IL-12p70 in plasma and/or sera (Supplementary Table 5). 
Because several studies have suggested to a critical role for IL-6 in MDE, we 
specifically investigated whether the levels of IL-6 measured by multiplex assays were 
comparable to those measured by ELISA. In the serum samples, while no correlation was 
observed for all visits between Luminex® and ELISA platforms (Fig. 1A), the correlation was 
very robust between the MSD and ELISA (visit 1, Rho=0.781, p=4.86E-5; Fig. 1B). In 
plasma, again, the correlation never reached significance for Luminex®  (Fig. 1C) in contrast 
to the MSD (Fig. 1D). As a control, we also verified the high correlation between all serum 
and plasma sample measurements for ELISA (visit 1, Rho=0.826, p=7.12E-6; 
Supplementary Fig. 2C). 
 
3.5. Intra-individual variability in healthy subjects 
As a prerequisite for the possible use of the 31 analytes that we have assayed as trait or 
state biomarkers in psychiatric diseases, we investigated whether their levels were stable 
over time in healthy individuals. Therefore, we calculated the ICC (Table 6). For some 
analytes, we could confirm intra-individual stability during a 30-week follow-up in healthy 
subjects on the basis of the convergent results in serum and plasma or between platforms 
(Eotaxin, bFGF, G-CSF, GM-CSF, IL-1β, IL-4, IL-5, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, 
MIP-1α, MIP-1β, RANTES, and TNF), whereas for others, intra-individual variability overtime 
in healthy subjects is most likely the rule (IL-8, IL-10, IP-10). As an example, the discrepancy 
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between the very low intra-individual stability of IL-8 across time in both serum and plasma 
and the strong stability of TNF is shown on Supplementary Fig. 3. Additionally, for some 
analytes, the results were discordant according to either the biofluid analyzed (i.e., serum 
versus plasma) or the platform used to assay the analyte (IFN-γ, IL-6, IL-10, IL-13, IL-16, IL-
17, PDGF-BB, VEGF). As an illustration, the poor to intermediate stability of both serum and 
plasma IL-6 measured on the MSD platform is represented on Fig. 1E and 1F. To confirm the 
level of stability for some of the most studied cytokines in the field of neuropsychiatry, we 
determined the ICC from serum and plasma samples of 10 additional healthy subjects during 
the 30 week-follow-up period assayed with the MSD platform. As shown in Supplementary 
Table 6, except for TNF-β, which was ultimately found to be stable in sera, we confirmed all 
the other trends described above. 
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4. Discussion 
To our knowledge, this is the first investigation of the stability of protein biomarker candidates 
in healthy individuals over time based on multiplex cytokine profiling. We also measured 
these target proteins in both sera and plasma from patients with a psychiatric disorder 
because these subjects present specific biological characteristics comparable with other 
infectious or pure inflammatory diseases. Meta-analyses that included both sera and plasma 
samples have previously identified only small to moderate effects on the cytokine levels 
within psychiatric populations (Dowlati et al., 2010; Ducasse et al., 2015a; Hiles et al., 2012; 
Valkanova et al., 2013). As a consequence, there is a great need in immuno-psychiatric 
studies for tools that may have the abilities to detect such low levels and small mean 
differences.  
Not much is known about physiological variations of circulating inflammatory signaling 
proteins in healthy individuals over weeks, months or even years. Nevertheless, contrary to 
the intuitive idea that many biological processes are not prone to variability outside of 
pathological situations, we have found that the concentrations of at least a few circulating 
factors exhibited intra-individual variability in healthy subjects. This was the case for IFN-γ, 
IL-6, IL-8, IL-10 and IP-10. In the case of IL-8, a similar concern was raised in previous 
investigations (Epstein et al., 2013; Gu et al., 2009; Hofmann et al., 2011). Therefore, when 
comparing the values of these cytokines in patients with control subjects, a single time point 
is not adequate to evaluate these cytokines as potential biomarkers.  
We have also confirmed early reports that showed discrepancies between the 
technical precision of multiplex technologies using calibrator samples and the heterogeneous 
platform assay performance with complex human body fluids (Nechansky et al., 2008; 
Toedter et al., 2008). On the one hand, our results confirmed both manufacturer’s 
information and previous work based on lyophilized cytokine standards (Chowdhury et al., 
2009). On the other hand, unexpectedly, dissimilar results and heterogeneous performances 
were obtained for human sera and plasma. 
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Neither platform demonstrated any clear advantage over the other one tested, but 
some trends were observed. The sensitivity was generally higher for the V-PLEX® platform, 
compared to Luminex® platform, as previously reported (Breen et al., 2011; Chowdhury et 
al., 2009). Despite the large concentration range obtained for the Luminex® standard curves, 
the slope steepness was higher with V-PLEX® for the low concentrations, and a better 
conservation of linearity was achieved (Supplementary Figure 1, Table 1). These results 
reflected a better capacity to detect low-abundance cytokines. For some assays, the proteins 
could not be detected in more than 60% of the tested sera (Table 2). Indeed, both platforms 
failed to robustly detect the GM-CSF, IL-1β, IL-2 and IL-5 cytokines for which previous 
investigations had reported significant variations in expression either during MDE treatment 
or at baseline in comparison to healthy controls (Biancotto et al., 2013; Dahl et al., 2014; 
Hernandez et al., 2008; Schmidt et al., 2014; Shelton et al., 2015). These types of 
inconsistency in the results have already been reported (Breen et al., 2011; Chaturvedi et al., 
2011; Dabitao et al., 2011; Dupuy et al., 2013; Fu et al., 2010). In particular, the consensus 
that the detection of IL-1β suffers from poor performances is of importance. An inflammatory 
cytokine could be a sensitive biomarker for a depressive mood even in healthy subjects 
(Katsuura et al., 2011). It is also possible that such a cytokine could contribute to the 
depressive symptoms, and its use as a biomarker could even reveal how antidepressants 
block the effects of inflammation on the brain (Hannestad et al., 2011; Hernandez et al., 
2013). However, a lack of reliability in the measurements weakens the use of multiplex 
assays for clinical purposes. Moreover, using the same Bio-Plex cytokine reagent kit used in 
a previous study on healthy university students, we also confirmed the lack of detection of 
bFGF, IL-15 and MCP-1 in serum (Katsuura et al., 2010; Katsuura et al., 2011). 
The intra-assay reproductibility was heterogeneous among the cytokines and 
between the platforms (Tables 2 and 3). In contrast, the performance of both platforms was 
sufficiently consistent for IL-8, IL-10, TNF and VEGF, although there was a general 
advantage for V-PLEX® technology. Importantly, these factors have shown promise as 
biomarkers for MDE (Carvalho et al., 2015; Meyer et al., 2011; Young et al., 2014). 
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It has already been stressed out that the comparison of absolute cytokine 
concentration should be attempted only if used reagents were obtained from the same 
supplier (Khan et al., 2004), although even singleplex assays compared to multiplex assays 
from the same company can yield significantly different results (de Koning et al., 2012; 
Huttunen et al., 2014). Indeed, we confirmed that the absolute values of the proteins 
detected were different between the two tested technologies. Such discordance could be due 
to differences in the capture and/or detection antibodies and to a differential sensitivity to 
matrix interference (Dupuy et al., 2013; Khan et al., 2004). However, among the cytokines for 
which the quantification was consistent, we observed strong inter-platform correlations for IL-
8 and VEGF (Table 5), in accordance with previous findings (Chowdhury et al., 2009; 
Dabitao et al., 2011; Huttunen et al., 2014). We also confirmed the tight relationship between 
V-PLEX® and ELISA measurements for IL-6 (Bastarache et al., 2014; Huttunen et al., 2014). 
Very few studies have compared the serum and plasma concentrations of cytokines 
from the same individuals (Altara et al., 2015; Chaturvedi et al., 2011; Clendenen et al., 
2010; Dossus et al., 2009; Rosenberg-Hasson et al., 2014; Wong et al., 2008). In general, it 
has been found that these marker measurements are not interchangeable between serum 
and plasma. Consistent with these previous studies, we found that in most cases, the serum 
and plasma concentrations of the cytokines were not correlated (Table 4). Therefore, meta-
analyses should distinguish studies of serum samples from the ones that used plasma 
samples. Moreover, some investigators have reported that the plasma cytokine 
concentrations were generally higher than those measured in serum due to a higher non-
specific background observed in serum (Chaturvedi et al., 2011; Rosenberg-Hasson et al., 
2014; Wong et al., 2008). In our study, we have confirmed such a trend only for the 
Luminex® platform (Supplementary Table 5), which may explain why the detectability was 
better for that platform in plasma compared to sera (Tables 2 and 3).  
Our findings have several important technical and theoretical limitations. First, we 
could not compare exactly the same sets of cytokines on both platforms on the basis of the 
commercial availability, and it has previously been observed that assay performance 
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decreases with increasing numbers of markers on a panel (Chaturvedi et al., 2011). It will be 
important in the future to follow up with studies to compare larger sets of cytokines as similar 
to each other as possible, because recent investigations in the field of biomarker discovery 
have revealed new candidates for promising proteins. Secondly, we did not address the 
inter-assay variability on each platform, which is an important factor to consider especially 
when investigating large samples that cannot be processed with a single batch of reagents or 
for longitudinal studies when assaying the samples at different days over long periods of 
time. Third, our results should be considered to be preliminary on the basis of the relatively 
small sample size that makes any group comparison between healthy control and patients 
inappropriate. Of note, for the purpose of another study, all serum samples assayed in the 
present study, and obtained from healthy control and MDE patients at their first visit, have 
been tested again on the MSD platform with a different batch of reagents and a two-year 
interval (data not shown). The same panels of cytokines were assayed as well as an 
additional chemokine panel. A comparative analysis of old and new measurements of 
cytokine concentrations revealed robust correlations for IFN-γ, IL-6, IL-8, IL-10, IL-12p40, IL-
15, IL-16, TNF, TNF-β, and VEGF (data not shown), suggesting a strong inter-assay stability 
for these analytes on the MSD platform. Moreover, the new measurements for IP-10 and 
MIP-1β obtained on the MSD platform strongly correlated with previous measurements 
obtained with the Luminex platform (data not shown), suggesting that these assays exhibit 
low intra- and inter-assay variability on both platforms. 
When possible, we followed the manufacturer’s recommendations, and therefore 
used a different dilution factor for both the sera and plasma samples for the Bio-Plex (factor 
4) compared to the V-PLEX (factor 2.6) assays. This could explain, at least in part, the 
increased sensitivity of the latter. Nevertheless, it has been shown that (i) both serum and 
plasma inhibit the readouts, (ii) the inhibitory effect of the matrix is partly reversed by dilution, 
and (iii) this type of inhibition is much higher with the Luminex® system compared to the 
MSD assays (Rosenberg-Hasson et al., 2014). In addition, as previously noted in a few 
studies (Dossus et al., 2009; Dupuy et al., 2013; Toedter et al., 2008), the nature of the 
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capture/detection antibody reactivity is crucial. In fact, for some cytokines such as IL-4, IL-
12p70 and IL-17 the Bio-Plex assays invariably outperformed those of the V-PLEX in both 
sera and plasma, whereas for other analytes including bFGF, GM-CSF and IL-15, striking 
differences in the detectability between sera and plasma were observed. 
The detection range, measured as the ratio between the HLOQ and the LLOQ was 
over 1000 for all tested analytes on both platforms (Table 1). However, the relevant parts of 
the calibration curves that were used to determine the protein concentrations generally 
included only 2 points or less in the lower end of the curve. Therefore, for at least the key 
cytokines, the availability of ultrasensitive multiplex assays dedicated to the very low end of 
calibration curves would be a significant advance as some investigators began to set-up 
(Rivnak et al., 2015). A dynamic range of 0-20 pg/ml would be optimal. In addition, the high 
variability in the measurement may result from factors other than those driven by the 
technology. The observed differences between the platforms were unlikely to have resulted 
from variability within the samples themselves because we ensured that identical aliquots 
were used on both platforms, avoided extra cycles of freezing/thawing procedures, 
performed the multisite measurements within the same period, and limited the manipulations 
to an experienced operator. Nevertheless, a recent large multi-site study reported highly 
variable results despite assessment of identical samples with same batches of reagents and 
identical Luminex-based assays (Lynch et al., 2014). Therefore, we cannot totally exclude 
the operator on each platform as a source of the variability. 
Many non-pathological processes can transiently affect the concentration of 
cytokines, chemokines and growth factors. For example, diurnal rhythms have been reported 
to produce significant differences between serum and plasma (Altara et al., 2015; Chaturvedi 
et al., 2011; Clendenen et al., 2010; Rosenberg-Hasson et al., 2014; Wong et al., 2008). For 
this reason, all of the subjects in our control and patient cohorts were examined under the 
same fasting conditions in the morning. Nevertheless, more labile factors could alter the 
cytokine concentrations within the few minutes prior to the blood collection. Among those 
factors, brief natural stresses in healthy individuals have been shown to affect circulating 
R. Belzeaux et al. 
 21 
cytokine levels (Katsuura et al., 2010). It is thus possible that some of the fluctuations that we 
observed were in fact driven by some physiological stress reaction that need to be further 
demonstrated.  
As a consequence, we feel that these results could underscore the necessity to 
perform assays in duplicates when using such multiplex platforms and to provide clear 
information regarding the intra-assay reliability within samples. Moreover, to avoid premature 
positive or negative conclusions, attention needs to be paid to the intra-individual variability. 
Longitudinal follow-up studies with repetitive measures may be a solution to overcome these 
issues. However, we cannot rule out the possibility that for some cytokines, the stochastic or 
cyclic variations in protein concentrations measured in healthy adults may stabilize with 
disease, in which case the stability could become a marker for the pathological condition. 
Finally, even after controlling for all previously defined potential biases, cross validation using 
another method, such as ELISA, may also be necessary (Leng et al., 2008; Zhou et al., 
2010), as demonstrated in our data by the potential lack of correlation between platforms for 
TNF and IL-10 (Table 5).  
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5. Conclusions 
Although they have received considerable interest for exploratory studies in the field of 
psychiatry and behavioral sciences, multiplex platforms have to be considered with caution. 
Any preliminary results would have to be interpreted rigorously according to current 
performance limits and would obviously require validation by standard ELISA methods. In 
addition, the issue of circulating protein stability in normal healthy subjects is not trivial. Any 
candidate biomarker for a neuropsychiatric disease would need to be validated over 
repeated measurements in healthy controls a low level of variability. 
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Figure Legend 
Figure 1. IL-6 correlations between singleplex and multiplex methods and the intra-individual 
variability across time. Scatterplot of the concentrations of the serum IL-6 analyzed using 
ELISA and either Luminex® (A; Rho=-0.061; p=0.844) or MSD (B; Rho = 0.781; p = 4.86E-
5). Scatterplot of the concentrations of the plasma IL-6 analyzed using ELISA and either 
Luminex® (C; Rho = 0.330; p = 0.181) or MSD (D; Rho = 0.767; p = 1.16E-3). The intra-
individual stability of the serum (E) and plasma (F) IL-6 concentrations measured on the 
MSD platform at inclusion (V1), and 2 (V2), 8 (V3) and 30 weeks later (V4).  
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Table1 Dynamic range and intra-assay CVs of the standard calibrators on 
the Luminex and MSD platforms. 
 
Analyte   Luminex   MSD 
 
LLOQ-ULOQ 
(pg/ml) 
detection 
range 
CV 
(%) 
linearity 
(%) 
 LLOQ-ULOQ 
(pg/ml) 
detection 
range 
CV 
(%) 
linearity 
(%) 
Eotaxin 1.72-7047 4097 4.5 91.1      
bFGF 14.3-14649 1024 3.4 104      
G-CSF 1.73-51920 30012 4.1 91.1      
IL-1RA 1.85-121425 65635 5.6 81.8      
IL-9 1.24-22978 18531 4.0 79.3      
IP-10 1.3-21311 16393 4.1 95.3      
MCP-1 13.5-27412 2030 3.6 73.7      
MIP-1α 0.58-2387 4116 2.7 94.0      
MIP-1β 1.11-6448 5809 2.7 88.1      
PDGF-BB 1.07-20331 19001 5.2 87.1      
RANTES 3.62-14838 4099 3.3 103      
IL-1α      0.09-405 4500 5.7 97.1 
IL-12p40      0.75-3220 4293 3.9 98.2 
IL-16      0.62-2810 4532 4.4 122 
TNF-β      0.14-632 4514 3.3 103 
GM-CSF 0.66-13149 19923 3.5 74.9  0.23-996 4330 4.7 96.8 
IFN-γ 3.62-34365 9093 4.5 100  0.33-1460 4424 4.0 92.5 
IL-1β 0.08-7731 96638 4.8 86.8  0.12-495 4125 3.6 94.6 
IL-2 4.75-19450 4095 2.2 71.7  0.32-1460 4563 3.3 93.2 
IL-4 0.2-4149 20745 4.7 94.5  0.05-262 5240 6.4 97.2 
IL-5 0.8-13069 16336 4.8 108  0.20-912 4560 4.6 95.3 
IL-6 1.41-26740 18965 2.7 80.3  0.16-767 4794 3.1 108 
IL-7 0.26-16792 64590 5.7 95.7  0.15-838 5587 5.4 102 
IL-8 0.35-39280 112229 5.0 79.2  0.12-500 4167 3.4 97.1 
IL-10 3.39-35130 10363 3.1 75.5  0.08-334 4175 4.5 92.4 
IL-12p70 2.33-38575 16556 4.6 77.5  0.10-421 4210 4.0 92.8 
IL-13 0.43-6976 16220 3.8 86.5  0.61-626 1026 4.2 133 
IL-15 6.49-6647 1024 4.9 63.3  0.17-779 4582 4.0 102 
IL-17 6.16-32716 5311 3.1 82.9  1.38-6010 4355 4.9 103 
TNF 0.93-60786 65361 3.7 88.9  0.07-317 4529 5.1 95.6 
VEGF 2.37-38806 16374 3.7 75.9  0.24-1020 4250 5.1 121 
CV < 5% are indicated in bold. 
Analytes with CV < 5% in at least one platform are indicated in bold. Analytes with CV < 5 % in both 
platforms are underlined. 
Table 1
Table 2 Proportion of serum samples within the detection range and 
intra-assay variability. 
 % of samples within the detection 
range 
 Intra-assay CV 
(%) 
 Luminex  MSD  Luminex MSD 
 Patient Control  Patient Control    
Eotaxin 100 100     5.86  
bFGF 12.5 11.1     ND  
G-CSF 77.5 91.7     11.3  
IL-1RA 90.0 55.6     15.3  
IL-9 100 100     13.6  
IP-10 100 100     3.58  
MCP-1 2.50 0     ND  
MIP-1α 40.0 47.2     16.1  
MIP-1β 100 100     4.04  
PDGF-BB 100 100     4.99  
RANTES 75.0 58.3     9.05  
IL-1α    50.0 44.7   31.9 
IL-12p40    100 100   4.83 
IL-16    100 100   4.27 
TNF-β    65.0 71.1   15.5 
GM-CSF 0 0  17.5 5.26  ND ND 
IFN-γ 0 0  100 100  ND 4.78 
IL-1β 57.5 58.3  40.0 44.7  28.5 57.7 
IL-2 27.5 36.1  7.5 15.8  ND ND 
IL-4 100 100  17.5 15.8  17.5 ND 
IL-5 40.0 47.2  27.5 13.2  15.4 ND 
IL-6 72.5 36.1  95.0 94.7  19.7 11.3 
IL-7 100 88.9  100 100  20.1 5.13 
IL-8 100 100  100 100  10.5 4.49 
IL-10 70.0 69.4  100 100  12.8 10.0 
IL-12p70 100 100  35.0 26.3  11.2 ND 
IL-13 100 100  34.9 10.5  14.4 ND 
IL-15 0 0  100 100  ND 3.37 
IL-17 77.5 83.3  60.0 42.1  21.8 19.2 
TNF 97.5 100  97.5 100  14.1 5.86 
VEGF 97.5 100  100 100  11.0 3.02 
Total 18/27 15/27  12/20 11/20  13/27 10/20 
Analytes that were above the LLOQ in at least 60% of serum samples are indicated in bold. Among 
these cytokines, those exhibiting CVs ≤ 15% on at least one platform are underlined. CVs were not 
determined (ND) for cytokines that were above the LLOQ in less than 40% of both control and 
patient samples.  
 
Table 2
Table 3 Proportion of plasma samples within the detection range and 
intra-assay variability. 
 % of samples within the detection 
range 
 Intra-assay CV 
(%) 
 Luminex  MSD  Luminex MSD 
 Patient Control  Patient Control    
Eotaxin 100 100     5.58  
bFGF 100 95.8     7.43  
G-CSF 100 100     19.8  
IL-1RA 100 100     5.68  
IL-9 100 100     11.3  
IP-10 100 100     6.12  
MCP-1 13.8 13.9     ND  
MIP-1α 100 100     5.36  
MIP-1β 100 100     3.92  
PDGF-BB 100 100     6.10  
RANTES 100 97.2     4.68  
IL-1α    77.5 62.5   26.9 
IL-12p40    100 100   4.36 
IL-16    100 100   4.29 
TNF-β    76.3 80.0   16.6 
GM-CSF 90 97.2  31.3 32.5  17.6 ND 
IFN-γ 100 100  100 100  7.53 10.9 
IL-1β 100 100  10.0 7.50  6.83 ND 
IL-2 0 0  2.50 18.8  ND ND 
IL-4 100 100  2.50 0.00  7.86 ND 
IL-5 100 100  86.3 82.5  8.95 20.1 
IL-6 82.5 90.3  78.8 83.8  12.0 10.9 
IL-7 100 100  100 100  9.16 7.68 
IL-8 100 100  100 100  9.11 5.57 
IL-10 92.5 94.4  86.3 85.0  9.98 16.6 
IL-12p70 97.5 98.6  22.5 7.50  11.5 ND 
IL-13 100 100  32.5 42.5  5.26 ND 
IL-15 41.2 61.1  100 100  17.2  3.99 
IL-17 100 98.6  57.5 45.0  8.93 17.3 
TNF 100 100  100 98.8  7.18 10.1 
VEGF 95.0 100  100 100  9.76 4.76 
Total 24/27 25/27  13/20 13/20  22/27 9/20 
Analytes that were above the LLOQ in at least 60% of either control or patient plasma samples are 
indicated in bold. Among these cytokines, those exhibiting CVs ≤ 15% on at least one platform are 
underlined. CVs were not determined (ND) for cytokines that were above the LLOQ in less than 40% 
of both control and patient samples.  
 
Table 3
Table 4 Correlation of measurements between sera and plasma 
samples. 
 Luminex MSD  
 Rho p-value  Rho p-value  
Eotaxin 0.902 5.40E-8     
IL-1RA -0.072 7.83E-1     
IL-9 0.415 6.90E-2     
IP-10 0.767 7.98E-5     
MIP-1β 0.710 8.00E-5     
PDGF-BB 0.206 3.84E-1     
RANTES 0.464 8.13E-2     
IL-12p40    0.860 1.16E-6  
IL-16    0.415 6.88E-2  
IFN-γ    0.967 4.10E-12  
IL-4 0.162 4.94E-1     
IL-6 0.063 8.46E-1  0.838 5.01E-5  
IL-7 -0.133 5.75E-1  -0.200 5.80E-1  
IL-8 0.116 6.28E-1  -0.205 3.87E-1  
IL-10 0.556 1.11E-2  0.564 1.84E-2  
IL-12p70 0.290 2.14E-1     
IL-13 0.797 2.60E-5     
IL-15    0.750 1.38E-4  
TNF 0.093 6.98E-1  0.684 8.77E-4  
VEGF 0.174 4.77E-1  0.535 1.50E-2  
Total  5/16   7/10  
Cytokines that exhibited significant correlation in either platform according to Spearman non-
parametric test were indicated in bold.  
 
Table 4
Table 5 Correlation of measurements between the Luminex and MSD 
platforms. 
 Serum Plasma  
 Rho p-value  Rho p-value  
IFN-γ    -0.229 3.32E-1  
IL-6    0.632 1.15E-2  
IL-7    0.236 5.11E-1  
IL-8 0.898 7.74E-8  -0.202 3.92E-1  
IL-10 0.098 6.82E-1  0.145 5.80E-1  
TNF -0.273 2.44E-1  0.289 2.17E-1  
VEGF 0.871 5.95E-7  0.730 3.90E-4  
Cytokines that exhibited significant correlation in either platform according to Spearman non-
parametric test were indicated in bold.  
 
Table 5
Table 6 Variability of analyte concentration in healthy subjects during a 
30-week period. 
 
 Serum  Plasma 
 Luminex MSD  Luminex MSD 
Eotaxin 0.930   0.974  
bFGF ND   0.958  
G-CSF 0.731   0.800  
IL-1RA ND   0.033  
IL-9 0.902   0.898  
IP-10 0.265   0.140  
MIP-1 α ND   0.969  
MIP-1β 0.913   0.736  
PDGF-BB 0.873   0.468  
RANTES ND   0.899  
IL-12p40  0.874   0.826 
IL-16  0.763   0.032 
TNF-β  -0,02a   0.857 
GM-CSF ND ND  0.860 ND 
IFN-γ ND -0.02  0.973 0.068 
IL-1 β ND ND  0.960 ND 
IL-4 0.804 ND  0.901 ND 
IL-5 ND ND  0.965 ND 
IL-6 ND 0.304  0.954 0.044 
IL-7 ND 0.921  0.946 0.608 
IL-8 0.049 0.068  0.894 -0.01a 
IL-10 0.140 -0.06a  0.962 0.105 
IL-12p70 0.833 ND  0.897 ND 
IL-13 0.538 ND  0.886 ND 
IL-15 ND 0.677  0.950 0.788 
IL-17 ND 0.469  0.954  
TNF 0.425 0.867  0.956 0.737 
VEGF 0.888 0.974  0.510 0.447 
aSome negative values for the ICC should be interpreted as providing poor agreement (Giraudeau, 
1996). Analytes in bold indicate the intra-indivdual stability considering an ICC ≥ 0.55 for both the 
sera and plasma samples with either one or both platforms. Statistical tests were not determined 
(ND) for analytes that were either above the LLOQ in less than 40% of control samples or that 
provided CV of duplicates > 20%. 
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